TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Imagion Biosystems Ltd. ( (AU:IBX) ) is now available.
Imagion Biosystems has issued a cleansing notice for 10,000,000 new ordinary shares as part of a Convertible Securities Agreement with Mercer Street Global Opportunity Fund, LLC. This issuance is part of their compliance with the Corporations Act, ensuring transparency and adherence to regulatory requirements. The move is expected to bolster Imagion’s financial position, potentially enhancing its market presence and operational capabilities in the medical imaging sector.
The most recent analyst rating on (AU:IBX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Imagion Biosystems Ltd. stock, see the AU:IBX Stock Forecast page.
More about Imagion Biosystems Ltd.
Imagion Biosystems Limited is a clinical-stage medical imaging company focused on transforming cancer diagnosis and treatment. The company is developing MagSense®, an innovative MRI imaging agent that uses non-radioactive, bio-safe magnetic nanoparticles to enhance diagnostic accuracy for various cancers, including HER2+ breast cancer, prostate, and ovarian cancers.
Average Trading Volume: 9,370,432
Technical Sentiment Signal: Sell
Current Market Cap: A$9.83M
See more insights into IBX stock on TipRanks’ Stock Analysis page.